Thermopylae Holdings Ltd. bought $580K of AbCellera Biologics (ABCL)
Executed Feb 26, disclosed Feb 27, 1 day later.
Over the 21 trading sessions from the disclosed entry session (Feb 27), the stock returned -4.9% (delay-adjusted); from the execution session (Feb 26), +5.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Thermopylae Holdings Ltd. (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in AbCellera Biologics Inc. (ABCL). Across 2 priced purchase filings, the average 21-session return was +0.0% from execution and -5.2% from disclosure (delay-adjusted; derived). The largest single filing was $580K of ABCL (177,457 sh × $3.27, as filed), executed Feb 26.
Healthcare · AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the Unit…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→38,000 sh × $3.44
Exec Feb 27
Filed Mar 2 · 2:16 PM ET ABCLPURCHASE AbCellera Biologics Inc. $742K
343,631 sh × $2.16
Exec Mar 11 2025
Filed Mar 11 2025 · 5:30 PM ET